Cargando…

CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls

Pharmacogenetic variants can alter the mechanism of action (pharmacodynamic gene variants) or kinetic processes such as absorption, distribution, metabolism and elimination (pharmacokinetic gene variants). Many initial successes in precision medicine occurred in the context of genes encoding the cyt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ellithi, Moataz, Baye, Jordan, Wilke, Russell A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444625/ https://www.ncbi.nlm.nih.gov/pubmed/32723143 http://dx.doi.org/10.2217/pgs-2020-0046

Ejemplares similares

Evaluation of race and ethnicity disparities in outcome studies of CYP2C19 genotype-guided antiplatelet therapy
por: Nguyen, Anh B., et al.
Publicado: (2022)

Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention
por: Cavallari, Larisa H., et al.
Publicado: (2018)

CYP2C19 Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings
por: Beitelshees, Amber L., et al.
Publicado: (2022)

The role of CYP2C19 genotyping to guide antiplatelet therapy following ischemic stroke or transient ischemic attack
por: McDermott, John H, et al.
Publicado: (2022)

Evaluating the Extent of Reusability of CYP2C19 Genotype Data among Patients Genotyped for Antiplatelet Therapy Selection
por: Beitelshees, Amber L., et al.
Publicado: (2020)

Cost-effectiveness of CYP2C19 genotyping to guide antiplatelet therapy for acute minor stroke and high-risk transient ischemic attack
por: Cai, Zeling, et al.
Publicado: (2021)

Frequency and Clinical Outcomes of CYP2C19 Genotype-Guided Escalation and De-escalation of Antiplatelet Therapy in a Real-World Clinical Setting
por: Martin, Jesse, et al.
Publicado: (2019)

Clinical Utility of CYP2C19 Genotype-Guided Antiplatelet Therapy in Patients at Risk of Adverse Cardiovascular and Cerebrovascular Events: A Review of Emerging Evidence
por: Gower, Megan N, et al.
Publicado: (2020)

Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy
por: Al-Rubaish, Abdullah M., et al.
Publicado: (2020)

Personalized Antiplatelet Therapy Based on CYP2C19 Genotypes in Chinese ACS Patients Undergoing PCI: A Randomized Controlled Trial
por: Shi, Xiujin, et al.
Publicado: (2021)

CYP2C19 genotype and platelet aggregation test-guided dual antiplatelet therapy after off-pump coronary artery bypass grafting: A retrospective cohort study
por: Yao, Haoyi, et al.
Publicado: (2022)

Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis
por: Bauer, Tim, et al.
Publicado: (2011)

Management of Bleeding Events Associated with Antiplatelet Therapy: Evidence, Uncertainties and Pitfalls
por: Godier, Anne, et al.
Publicado: (2020)

Tailored Thienopyridine Therapy: No Urgency for CYP2C19 Genotyping
por: Fontana, Pierre, et al.
Publicado: (2013)

Personalized antiplatelet therapy with P2Y(12) receptor inhibitors: benefits and pitfalls
por: Winter, Max-Paul, et al.
Publicado: (2015)

Low-Dose Radiation Therapy for COVID-19: Promises and Pitfalls
por: Venkatesulu, Bhanu P, et al.
Publicado: (2020)

Therapeutic drug monitoring and CYP2C19 genotyping guide the application of voriconazole in children
por: Chen, Xiaomin, et al.
Publicado: (2022)

Analysis of the Guiding Role of CYP2C19 Gene Combined With Platelet Function Detection in Antiplatelet Therapy in Patients With Complex Coronary Artery Disease After PCI
por: Yu, Jiancai, et al.
Publicado: (2022)

Methodology for clinical genotyping of CYP2D6 and CYP2C19
por: Carvalho Henriques, Beatriz, et al.
Publicado: (2021)

CYP2C19 genotype-directed P(2)Y(12) inhibitor antiplatelet therapy normalizes risk for major adverse cardiovascular events after percutaneous coronary intervention
por: Stys, Tomasz P., et al.
Publicado: (2021)

The promise and pitfalls of the internet for cognitive behavioral therapy
por: Andersson, Gerhard
Publicado: (2010)

Medication Therapy Management Programs: Promises and Pitfalls
por: Ai, Amy L., et al.
Publicado: (2014)

Distribution of CYP2C19 polymorphisms in Mongolian and Han nationals and the choice of specific antiplatelet drugs
por: Li, Jing, et al.
Publicado: (2017)

Antiplatelet response to clopidogrel is associated with a haplotype in CYP2C19 gene in Pakistani patients
por: Ahmed, Sagheer, et al.
Publicado: (2022)

Promise and pitfalls of the Immunochip
por: Cortes, Adrian, et al.
Publicado: (2011)

The Promise and Pitfalls of Prophages
por: McKerral, Jody C., et al.
Publicado: (2023)

Correction: Methodology for clinical genotyping of CYP2D6 and CYP2C19
por: Henriques, Beatriz Carvalho, et al.
Publicado: (2022)

Metoprolol and CYP2D6: A Retrospective Cohort Study Evaluating Genotype-Based Outcomes
por: Collett, Savannah, et al.
Publicado: (2023)

Promises and Pitfalls of In Vivo Evolution to Improve Phage Therapy
por: Bull, James J., et al.
Publicado: (2019)

Cellular Therapies in Solid Organ Allotransplantation: Promise and Pitfalls
por: Shaw, Brian I., et al.
Publicado: (2021)

Impact of Implementing CYP2C19 Genotype-Guided Antiplatelet Therapy on P2Y(12) Inhibitor Selection and Clinical Outcomes in Acute Coronary Syndrome Patients After Percutaneous Coronary Intervention: A Real-World Study in China
por: Zhang, Yi, et al.
Publicado: (2021)

DNA Barcoding: Promise and Pitfalls
por: Moritz, Craig, et al.
Publicado: (2004)

Personalized Medicine: Promises and Pitfalls
por: Huang, Jean
Publicado: (2017)

The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel
por: Pettersen, Alf-Aage R, et al.
Publicado: (2011)

Platelet Function Testing-Guided Antiplatelet Therapy
por: Lenk, Ekaterina, et al.
Publicado: (2014)

Influence of CYP2C19 genetic variants and smoking on dual antiplatelet efficacy in patients with coronary artery disease
por: Cheng, Yujing, et al.
Publicado: (2023)

microRNAs as Promising Biomarkers of Platelet Activity in Antiplatelet Therapy Monitoring
por: Krammer, Teresa L., et al.
Publicado: (2020)

CYP2C19 Genotype Is Not Associated With the Risk of Microscopic Colitis
por: DARLINGTON, K. C., et al.
Publicado: (2023)

The impact of CYP2C19 genotype on phenoconversion by concomitant medication
por: de Jong, Laura M., et al.
Publicado: (2023)

Use of Clopidogrel and Proton Pump Inhibitors Alone or in Combinations in Persons with Diabetes in Denmark; Potential for CYP2C19 Genotype-Guided Drug Therapy
por: Westergaard, Niels, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2fovjqj5mm5al9c85dcunnkipn